FindTrial
Sign In

Clinical effect of early use low dose spironolactone in the treatment of patients with NYHA class I - II heart failure

Clinical effect of early use low dose spironolactone in the treatment of patients with NYHA class I - II heart failure

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004178
Enrollment
Unknown
Registered
2014-01-21
Start date
2014-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Group A:Routine treatment
Group B:Routine treatment+spironolactone

Sponsors

Xianju People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Aged 40 ~ 80 years old; ACEI has been applied, B receptor blocker, and added to the maximum tolerated dose or target dose; NYHA I ~ II; before entering the group did not use Spironolactone.

Exclusion criteria

Exclusion criteria: Acute myocardial infarction induced heart failure; nearly 6 months occurred in acute decompensated heart failure; serum potassium >5.0 mmol/L; past after application of ARA potassium >6.0mmol/L; estimated glomerular filtration rate (eGFR) <30 mlfmin; patients with valvular heart disease, congenital heart disease, acute viral myocarditis, pacemaker implantation and malignant tumor.

Design outcomes

Primary

MeasureTime frame
BNP;Vital Sign(HR, BP);Bichemical Indicator (liver function, SCr, Bun, CK-MB);ECG;echocardiography;Clinical profile;—

Countries

China

Contacts

Public ContactDU Bin

Xianju People's Hospital

68794301@qq.com+86 13586206463

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026